Date: 2015-12-15
Type of information: Research agreement
Compound: new therapeutics for Gram-negative bacteria
Company: Evotec (Germany) Spero Therapeutics (USA - MA)
Therapeutic area: Infectious diseases
Type agreement: research - development
Action mechanism:
Disease:
Details: • On December 15, 2015, Evotec announced an extension of an existing collaboration with Spero Therapeutics aimed at discovering and developing new and ground-breaking therapeutics for Gram-negative bacteria to treat serious infections and address the growing threat to global public health resulting from antibiotic resistance. Under the terms of the agreement, Evotec will complement Spero’s capabilities by providing early-stage research support for key projects such as Spero’s Potentiator programme which is focused on increasing the potency of existing drugs against multi-drug resistant Gram-negative bacteria. Infections resulting from Gram-negative bacteria is an area that has been without novel therapeutics or approaches in more than fourty years. In addition, Spero will direct Evotec’s in vitro and in vivo infectious disease capabilities to advance its MvfR programme which focuses on two highly important bacterial processes, virulence and persistance.
Financial terms: The collaboration includes substantial research funding to Evotec and runs to the end of 2016. No further financial details were disclosed.
Latest news:
